HMN 2025: How Pulsed field ablation system shows promise for reducing ventricular tachycardia recurrence

Six-month outcomes from the Ventricular Catheter Ablation Study, the first-in-human evaluation of its FieldForce Ablation System for ventricular tachycardia (VT), have been published in Circulation. Results were also presented as a late-breaking trial at the 20th Annual International Symposium on Ventricular Arrhythmias (VT Symposium 2025), held in Philadelphia Oct. 10–11.

“This is the first time we’ve seen evidence that pulsed field ablation can reach deep scar tissue in the ventricle,” said Vivek Reddy, M.D., co-principal investigator, lead author, and electrophysiologist at Mount Sinai, New York.

VCAS is a prospective, multicenter feasibility trial evaluating the safety and performance of the FieldForce Ablation System in patients with VT. Unlike conventional approaches, the system delivers a proprietary high-voltage, short-pulse waveform designed to penetrate dense scar tissue while minimizing thermal injury.

Key Findings

• 82% freedom from recurrent VT/VF or ICD therapy
• 98% reduction in VT/VF burden (episodes)
• 11.5% had a primary safety event with 0 therapy-related complications

“While this remains an initial feasibility study, the six-month outcomes are highly encouraging. Achieving 82% freedom from recurrence and a 98% reduction in arrhythmia burden with a nonthermal, tissue-selective energy is a meaningful result in VT therapy. Importantly, this is the first time we’ve seen evidence that PFA can reach deep, transmural scar tissue in the ventricle, a long-standing challenge with existing energy sources,” said Reddy.

“These findings give me cautious optimism that with continued refinement, this approach could represent an important advance in the treatment of scar-related VT.”

With U.S. Food and Drug Administration’s (FDA) Breakthrough Device designation and acceptance into the FDA Total Product Life Cycle (TAP) Pilot Program, Field Medical is advancing this program toward a pivotal trial and a rigorous evaluation of high-voltage focal PFA in VT.

“It is rare for initial feasibility data to be published in Circulation, and this underscores both the rigor and the significance of the work,” said Steven Mickelsen, M.D., founder and chief technology officer of Field Medical. “Our mission has always been to unite scientific credibility with innovation. These findings mark an important milestone as we continue to evaluate pulsed field ablation for its potential to improve outcomes for patients with ventricular arrhythmias.”

Looking ahead, the company is evaluating additional applications of its FieldForce Ablation System beyond VT and expects to present initial feasibility findings in atrial fibrillation (AF) at a major scientific meeting in early 2026.

The FieldForce Ablation System features a single-point contact force PFA catheter with an innovative design utilizing proprietary FieldBending technology to deliver targeted, brief, high-intensity electric fields. This next-generation PFA technology was designed to deliver both precise targeted lesions and large volume transmural lesions in the ventricle.

Provided by
Field Medical, Inc.

The content is provided for information purposes only.